Epidemiology of Spondyloarthritis: A Review

Bakland, Gunnstein; Nossent, Jiri

doi:10.1007/s11926-013-0351-1

Cited by 62 publications

(45 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the 18-45 group the SpA is the disease with the highest prevalence of 79.5%; in particular, in the male population SpA is significantly higher (74% p=0.01) than RA (26%) while in females the two diseases are roughly equivalent. Moreover the female:male ratio of patients affected by SpA is 1:3 in agreement with data from the literature that show a higher prevalence of SpA in young males with a ratio female:male of 1:3 [29]. In the ≥67 age group females and males are 60.9% and 39.1% respectively.…”

Section: Discussionsupporting

confidence: 91%

“…In the female group RA shows a prevalence of 64.3% and SpA 35.7%. A higher prevalence of RA in females is reported in the literature: in women RA develops between 30-50 years with an incidence 3-5 times higher in females than males and this incidence tends to decrease with increasing age [29]. Therefore our results demonstrate that the study population is epidemiologically representative of the two autoimmune diseases both for sex and for age distribution.…”

Section: Discussionsupporting

confidence: 63%

See 1 more Smart Citation

Biologic therapies in rheumatic diseases: drug and anti-drug antibody levels and clinical efficacy

Lombardi¹,

Bernardoni²,

Bertolucci³

et al. 2017

J Autoimmun Cell Response

View full text Add to dashboard Cite

Background: The aim of this study was to evaluate the relevance of drug and anti-drug antibody detection in the clinical management of patients with rheumatoid arthritis (RA) and spondyloarthropaties (SpA) in treatment with anti-tumor necrosis factor alpha (TNFα) biologics. Methods and results:The study included 192 adult consecutive patients treated for at least 6 months with adalimumab (ADA) or etanercept (ETN) or infliximab (IFX); patients underwent clinical observations in the Rheumatologic Unit of 5 Hospitals in Tuscany. Their demographic and clinical characteristics to calculate DAS28 and BASDAI scores were collected. Drug levels and anti-drug antibodies (anti-drug Ab) were evaluated immediately before drug injection or infusion. A total of 192 patients were studied: 62 receiving IFX, 64 ADA, and 66 ETN with a mean age of 57 years (range 18-86 years); the study group was composed of 51% women. Forty percent of the patients were affected by RA, 60% by SpA. Altogether, 81% of patients demonstrated therapeutic drug levels. Anti-drug Ab were found in 19% of patients taking IFX, 10% taking ETN and 5% taking ADA. No significant correlation was found between anti-drug Ab presence and low drug levels, between anti-drug Ab and high DAS28 and BASDAI scores, as well as between low drug levels and high DAS28 and BASDAI scores. Conclusions: Low drug levels were found in 19% of the rheumatic patients and there were not correlations with presence of anti-drug Ab or patient's clinical status.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Discussionsupporting

confidence: 63%

Biologic therapies in rheumatic diseases: drug and anti-drug antibody levels and clinical efficacy

Lombardi¹,

Bernardoni²,

Bertolucci³

et al. 2017

J Autoimmun Cell Response

View full text Add to dashboard Cite

show abstract

“…A maior prevalência de pa- cientes com espondilite anquilosante em comparação com a artrite psoriásica também foi observada por Gallinaro et al 21 , que compararam dados de um estudo epidemiológico brasileiro com os dados de diversos países ibero-americanos. Diferentemente, Bakland & Nossent 22 encontraram que a prevalência de artrite psoriásica foi semelhante à da espondilite anquilosante em diversas regiões do mundo na população em geral. A incidência e a prevalência da espondilite anquilosante podem estar associadas à prevalên-cia do HLA B-27 na população.…”

Section: Discussionunclassified

Não adesão à terapia biológica em pacientes com doenças reumáticas no Sistema Único de Saúde em Minas Gerais, Brasil

2015

View full text Add to dashboard Cite

Resumo Neste estudo, buscou-se estimar e analisar fatores associados à não adesão ao tratamento com os medicamentos biológicos adalimumabe e etanercepte em pacientes portadores de doenças reumáticas atendidos pelo Sistema Único de Saúde de Minas Gerais, Brasil. Procedeu-se a estudo prospectivo não concorrente com base no registro de dispensação nas farmácias de pacientes adultos em início de tratamento. A taxa de não adesão foi estimada com utilização do método de proporção de dias cobertos (PDC), sendo considerados não aderentes pacientes com PDC < 0,8. Foram identificados 1.150 pacientes, sendo 64,3% portadores de artrite reumatoide, 8,5% de artrite psoriásica e 27,2% de espondilite anquilosante. A taxa de não adesão encontrada foi de 33,5% e os fatores associados foram idade entre 19-39 anos, sexo feminino, diagnóstico de artrite reumatoide e início de tratamento com etanercepte. Os resultados indicam uma alta taxa de não adesão ao tratamento, que pode originar piores resultados em saúde e implicar o aumento da utilização de cuidados e dos custos em saúde.

show abstract

“…Spondyloartropatie zapalne (SpA) to przewlekłe choroby charakteryzujące się zapaleniem stawów o zróżni-cowanym obrazie klinicznym, które w populacji ogólnej występują u 0,4-1,9% osób -częściej w krajach północ-nych niż południowych, co koreluje z obecnością antygenu zgodności tkankowej HLA-B27 w genotypach [1]. Na SpA częściej chorują mężczyźni niż kobiety, ale -jak wskazują najnowsze badania -przebieg zesztywniają-cego zapalenia stawów kręgosłupa (ZZSK) u kobiet jest cięższy i atypowy (dominuje ból uogólniony i entezopatie, a ból kręgosłupa jest mniej nasilony), także kobiety gorzej odpowiadają na leczenie [2].…”

Section: Wstępunclassified

New aspects of spondyloarthritis pathogenesis. Part I. Genetic factors and role of HLA-B27 molecules

Kontny¹

2014

Reumatologia

View full text Add to dashboard Cite

Badania z ostatnich lat weryfikują zrozumienie patogenezy spondyloartropatii zapalnych (SpA). Wskazują one, że tradycyjne podtypy tej choroby mają wspólny komponent patogenezy. Składają się na niego pewne wspólne uwarunkowania genetyczne (allele HLA-B27, warianty genów IL-23R, ERAP1, ERAP2), które omówiono w niniejszym artykule. Oprócz tego istnieją podobieństwa dotyczące czynników środowiskowych i mechanizmów immunologicznych, co będzie przedmiotem następnych opracowań. Zmienił się również pogląd na rolę cząsteczek HLA-B27 w patogenezie SpA. Cząsteczki HLA-B27 występują w formie klasycznej i nieklasycznej, jako pojedyncze łańcuchy ciężkie lub ich homodimery. Cząsteczki klasyczne prezentują antygeny własne i obce, inicjując nabytą odpowiedź immunologiczną, natomiast cząsteczki nieklasyczne indukują odpowiedź autozapalną. W artykule omówiono również to zagadnienie.

show abstract

Epidemiology of Spondyloarthritis: A Review

Cited by 62 publications

References 34 publications

Biologic therapies in rheumatic diseases: drug and anti-drug antibody levels and clinical efficacy

Biologic therapies in rheumatic diseases: drug and anti-drug antibody levels and clinical efficacy

Não adesão à terapia biológica em pacientes com doenças reumáticas no Sistema Único de Saúde em Minas Gerais, Brasil

New aspects of spondyloarthritis pathogenesis. Part I. Genetic factors and role of HLA-B27 molecules

Contact Info

Product

Resources

About